Sol-Gel Technologies (SLGL) Competitors $0.90 -0.15 (-14.44%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.02 (-1.94%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends SLGL vs. VTYX, CRBP, FTLF, NBTX, MNPR, TELO, SLDB, SAVA, BDTX, and ZURAShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Ventyx Biosciences (VTYX), Corbus Pharmaceuticals (CRBP), FitLife Brands (FTLF), Nanobiotix (NBTX), Monopar Therapeutics (MNPR), Telomir Pharmaceuticals (TELO), Solid Biosciences (SLDB), Cassava Sciences (SAVA), Black Diamond Therapeutics (BDTX), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry. Sol-Gel Technologies vs. Ventyx Biosciences Corbus Pharmaceuticals FitLife Brands Nanobiotix Monopar Therapeutics Telomir Pharmaceuticals Solid Biosciences Cassava Sciences Black Diamond Therapeutics Zura Bio Sol-Gel Technologies (NASDAQ:SLGL) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Is SLGL or VTYX more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -81.75%. Sol-Gel Technologies' return on equity of -27.17% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-81.75% -27.17% -22.49% Ventyx Biosciences N/A -54.94%-50.01% Does the media refer more to SLGL or VTYX? In the previous week, Ventyx Biosciences had 15 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 15 mentions for Ventyx Biosciences and 0 mentions for Sol-Gel Technologies. Ventyx Biosciences' average media sentiment score of 0.74 beat Sol-Gel Technologies' score of -1.00 indicating that Ventyx Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Sol-Gel Technologies Negative Ventyx Biosciences Positive Does the MarketBeat Community believe in SLGL or VTYX? Sol-Gel Technologies received 118 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 63.40% of users gave Sol-Gel Technologies an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformSol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% Ventyx BiosciencesOutperform Votes3146.97% Underperform Votes3553.03% Do analysts prefer SLGL or VTYX? Sol-Gel Technologies presently has a consensus target price of $5.00, indicating a potential upside of 445.26%. Ventyx Biosciences has a consensus target price of $10.00, indicating a potential upside of 408.91%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Ventyx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk and volatility, SLGL or VTYX? Sol-Gel Technologies has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Which has preferable earnings & valuation, SLGL or VTYX? Sol-Gel Technologies has higher revenue and earnings than Ventyx Biosciences. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$11.71M2.18-$27.24M-$0.34-2.70Ventyx BiosciencesN/AN/A-$192.96M-$2.36-0.83 Do insiders and institutionals believe in SLGL or VTYX? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 18.2% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummarySol-Gel Technologies beats Ventyx Biosciences on 11 of the 17 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.08M$6.55B$5.37B$9.09BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-2.759.4686.7617.45Price / Sales2.18318.651,278.6077.80Price / CashN/A22.6336.6032.90Price / Book0.555.034.924.62Net Income-$27.24M$154.90M$117.96M$224.76M7 Day Performance-27.22%2.08%2.19%2.84%1 Month Performance113.75%1.07%3.21%4.81%1 Year Performance-20.58%4.19%26.71%21.17% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies2.4632 of 5 stars$0.90-14.4%$5.00+456.5%-9.1%$25.03M$11.71M-2.6450Gap DownVTYXVentyx Biosciences2.9948 of 5 stars$1.95-6.3%$10.00+412.8%+2.5%$137.89MN/A-0.8330CRBPCorbus Pharmaceuticals4.3036 of 5 stars$11.30-4.2%$62.00+448.7%+69.1%$137.62M$880,000.00-2.4140Short Interest ↓FTLFFitLife Brands4.2438 of 5 stars$29.73-0.1%$40.00+34.5%+47.8%$136.70M$62.76M17.5920Positive NewsNBTXNanobiotix3.2157 of 5 stars$2.90+2.5%$12.00+313.8%-59.4%$136.69M$36.22M0.00100News CoveragePositive NewsGap UpMNPRMonopar Therapeutics1.7632 of 5 stars$25.69+1.3%$38.50+49.9%+1,457.4%$135.59MN/A-13.0410TELOTelomir PharmaceuticalsN/A$4.50+9.5%N/AN/A$133.25MN/A0.001Gap UpSLDBSolid Biosciences3.7474 of 5 stars$3.33-9.5%$15.30+359.5%-59.6%$133.05M$8.09M-1.10100News CoverageGap UpSAVACassava Sciences4.4512 of 5 stars$2.73-3.5%$111.50+3,984.2%-89.6%$131.34MN/A-1.9830BDTXBlack Diamond Therapeutics2.8859 of 5 stars$2.30+19.2%$15.50+573.9%-20.3%$130.15MN/A-1.7390High Trading VolumeZURAZura Bio3.6139 of 5 stars$1.99-7.9%$15.80+694.0%-58.8%$129.94MN/A0.003 Related Companies and Tools Related Companies Ventyx Biosciences Alternatives Corbus Pharmaceuticals Alternatives FitLife Brands Alternatives Nanobiotix Alternatives Monopar Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Solid Biosciences Alternatives Cassava Sciences Alternatives Black Diamond Therapeutics Alternatives Zura Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLGL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
